Health CarePharmaceuticals and Biotechnology
  • Price (USD)325.62
  • Today's Change12.90 / 4.13%
  • Shares traded5.45m
  • 1 Year change+39.77%
  • Beta0.3923
Data delayed at least 15 minutes, as of Jun 24 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

  • Revenue in USD (TTM)29.32bn
  • Net income in USD6.13bn
  • Incorporated1901
  • Employees35.00k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LLY:NYQ since
Protomer Technologies IncAnnounced14 Jul 202114 Jul 2021Announced38.39%--
Data delayed at least 15 minutes, as of Jun 24 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Regeneron Pharmaceuticals Inc16.51bn7.93bn66.72bn10.37k8.613.348.114.0470.5670.56146.35181.860.74831.623.661,592,216.0035.9625.6441.8729.9984.6588.5148.0639.114.27360.500.1194--89.1427.02129.8655.241.52--
Vertex Pharmaceuticals Incorporated7.95bn2.45bn72.51bn3.90k29.886.6428.069.129.499.4930.7042.680.60283.007.002,037,845.0018.5918.0122.0421.8787.9587.7730.8429.174.6047.320.04350.0022.0634.79-13.63--32.96--
Gilead Sciences, Inc.27.47bn4.52bn78.49bn14.40k17.483.9411.912.863.583.5821.7815.880.42084.097.121,907,778.006.888.358.0010.0275.7479.5616.3522.221.307.420.568258.7610.60-2.124,960.98-14.34-4.999.07
Zoetis Inc7.89bn2.07bn79.62bn12.10k38.8217.1131.5610.094.364.3616.599.890.57071.236.72652,148.8014.9713.7918.3616.0470.7668.7526.2323.941.5811.500.585422.5316.499.7324.3619.9317.1720.72
Amgen, Inc.26.32bn5.72bn129.86bn24.20k23.93141.7714.244.9310.1610.1646.561.710.43241.555.541,087,438.009.4011.0711.9313.4075.2179.2921.7530.881.096.640.975849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.96bn6.25bn165.41bn32.20k27.595.249.803.522.822.8221.1514.830.43594.726.551,458,385.005.822.677.163.2979.6274.1813.356.541.236.750.587163.849.0919.01177.589.43-4.355.22
Merck & Co., Inc.53.98bn13.91bn232.65bn68.00k16.785.6913.434.315.485.5921.2816.170.54662.565.98793,794.1014.097.6118.7210.1471.1170.9225.7816.061.1442.760.43786.0617.314.12173.1825.7922.487.49
AbbVie Inc56.73bn12.40bn264.09bn50.00k21.4416.2212.644.666.976.9731.919.220.38635.085.581,134,500.008.507.4610.909.4669.7872.0322.0118.110.7088.540.818397.8922.6916.99151.7114.1310.4417.93
Pfizer Inc.92.37bn25.42bn281.05bn79.00k11.293.409.183.044.434.3616.1114.740.53913.968.001,169,203.0014.866.6218.438.2560.4574.0427.5621.321.1381.490.305175.7295.169.00238.0525.516.285.39
Eli Lilly And Co29.32bn6.13bn297.13bn35.00k46.4131.8438.2810.136.746.7432.239.820.62551.994.92837,794.3013.0711.0817.9415.8074.4077.1620.9020.770.97659.830.635753.7515.405.94-9.8815.3111.4010.76
Data as of Jun 24 2022. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

35.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202267.22m7.07%
PNC Bank, NA (Investment Management)as of 31 Mar 202252.13m5.49%
BlackRock Fund Advisorsas of 31 Mar 202240.98m4.31%
SSgA Funds Management, Inc.as of 31 Mar 202233.75m3.55%
PRIMECAP Management Co.as of 31 Mar 202228.87m3.04%
Fidelity Management & Research Co. LLCas of 31 Mar 202228.73m3.02%
Wellington Management Co. LLPas of 31 Mar 202227.22m2.87%
Capital Research & Management Co. (World Investors)as of 31 Mar 202222.36m2.35%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202220.92m2.20%
State Farm Investment Management Corp.as of 31 Mar 202217.41m1.83%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.